These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Application of ISO 9002 and FDA's good manufacturing practices to general chemical manufacturing. Kauffman JM; Weiler ED Qual Assur; 1992 Jun; 1(3):213-6. PubMed ID: 1344676 [TBL] [Abstract][Full Text] [Related]
24. Remarks at the Food and Drug Law Institute's 48th Annual Conference. Niedelman SM Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089 [No Abstract] [Full Text] [Related]
25. Counterfeiting and piracy of pharmaceuticals. Grackin A IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698 [No Abstract] [Full Text] [Related]
26. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries. Schwemer WL; Lynch MA J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802 [No Abstract] [Full Text] [Related]
27. As Genzyme flounders, competitors and activist investors swoop in. Allison M Nat Biotechnol; 2010 Jan; 28(1):3-4. PubMed ID: 20062016 [No Abstract] [Full Text] [Related]
28. Recent developments in aluminium contamination of products used in parenteral nutrition. Gura KM; Puder M Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):239-46. PubMed ID: 16607123 [TBL] [Abstract][Full Text] [Related]
29. Manufacturing misdeeds cost Abbott record-breaking payment. Lewis C FDA Consum; 2000; 34(3):38-9. PubMed ID: 11521253 [No Abstract] [Full Text] [Related]
30. Report on the PQRI impurity characterization and quantification best practices survey. Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396 [No Abstract] [Full Text] [Related]
31. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories. Jimenez FA Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711 [No Abstract] [Full Text] [Related]
32. Business considerations in the development of probiotics. Hoffman FA Clin Infect Dis; 2008 Feb; 46 Suppl 2():S141-3; discussion S144-51. PubMed ID: 18181721 [TBL] [Abstract][Full Text] [Related]
33. Regulation of plasma derivatives in the U.S.A. Finlayson JS Dev Biol Stand; 1993; 81():277-81. PubMed ID: 8174815 [No Abstract] [Full Text] [Related]
35. Personal responsibility and the Food and Drug Law. Janssen WF FDA Consum; 1975 Nov; 9(9):10-3. PubMed ID: 10308122 [No Abstract] [Full Text] [Related]
36. Botanical drugs: a future for herbal medicines. Li W J Contemp Health Law Policy; 2002; 19(1):117-49. PubMed ID: 12733224 [No Abstract] [Full Text] [Related]
37. Standardization of forensic drug analyses. Frank RS; Gunn JW J Forensic Sci; 1974 Jan; 19(1):163-7. PubMed ID: 4854386 [No Abstract] [Full Text] [Related]
39. Drug development history, "overview," and what are GCPs? Heilman RD Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867 [TBL] [Abstract][Full Text] [Related]
40. The drug industry and drug effectiveness. Curran WJ N Engl J Med; 1970 Aug; 283(6):304-5. PubMed ID: 5427059 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]